ArticleHealth science reports2025
FDA-Approved Zuranolone: First Oral Treatment for Postpartum Depression, Ushering in a New Era of Hope; A Narrative Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregnanolone-Based Prodrugs as a Strategy for Neuroprotective Drug-Like Compounds: Pregnanolone Pyroglutamate and Its Age‑dependent Anticonvulsant Effects in the 6-hz Seizure Model in Immature Rats.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Postpartum depression (PPD) is a significant concern globally, emerging from various factors including hormonal changes, genetic influences, and environmental stressors. Conventional treatments such as psychotherapy and antidepressants have been the standard approach, but the recent U.S. Food and Drug Administration (FDA) approval of zuranolone presents a promising alternative with rapid onset of action and potential for increased treatment accessibility. This review aims to evaluate the efficacy and safety of zuranolone in treating PPD, considering its impact on symptom relief and patient outcomes. Methods: This review examines the multifaceted nature of PPD, focusing on its epidemiology, pathophysiology, and therapeutic interventions. Relevant literature was identified through systematic searches of databases, including PubMed and Google Scholar, using keywords related to PPD, hormonal changes, genetic factors, and treatment modalities. Results: Two rigorous phase 3 trials involving female participants diagnosed with PPD demonstrated that patients treated with zuranolone exhibited significantly greater improvement in depressive symptoms compared to those receiving a placebo. The treatment effect persisted 4 weeks after the last dose of zuranolone, indicating sustained benefits. Zuranolone showed notable effectiveness in reducing PPD symptoms as early as the third day of therapy. Its ease of administration, dosage flexibility, and potential for early intervention contribute to its promise in addressing severe PPD. Conclusion: PPD poses a significant challenge globally, and zuranolone represents a historic advancement in its treatment. While conventional therapies remain vital, zuranolone offers rapid relief and increased treatment accessibility. However, concerns regarding its safety for breastfeeding women and potential side effects necessitate further research and cautious use. Despite these challenges, zuranolone offers hope for improved outcomes and enhanced quality of life for individuals affected by PPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.